CONCLUDING REMARKS
Repeatedly since the genesis of the anti-aging medical movement in 1991, the media has sought to demonize the use of hormone replacement therapies in healthy but deficient adults. Relying on partisan – and often misinformed – critics, the media fuel and encourage hysteria among the public, which thereby results in a climate of misguided federal and state actions that seek to restrict these safe, proven, life-enhancing therapies.
Attempts to criminalize the practice of medicine where variations to State Board-favored traditional care threaten the continued advancement of innovative medicine. In these situations, there are no injured patients and no victims yet criminal proceedings are waged against progressive health professionals. State officials abuse their authority in recasting minor administrative issues as criminal acts; this is unjust and may be considered as criminal abuse of their publicly elected positions. Sensationalization by media confuses the public, with false allegations suggesting that HRT in clinically documented cases of adult deficiency syndromes equates to the abuse of performance-enhancing anabolic steroids.
The American Academy of Anti-Aging Medicine (A4M) is resolute in defending the rights of the patient working in conjunction with their physician in choosing any and all justifiable therapies, drugs and interventions which can be shown to improve either the quality or duration of the human lifespan or the form and function of the individual's physiology in order to achieve greater vitality and health at every age. It is in fact the physician's duty to act as an advocate for the patient's right to obtain the full lawful measure of scientific medical therapeutics necessary for optimum health and personal freedom of choice in healthcare.
The observation by George Orwell (1903-1950), English novelist, in the prognostic classic novel 1984, that: “War is peace. Freedom is slavery. Ignorance is strength” predicts that In a world where lies are supported by the establishment, to stand firm for truth is a dangerous and revolutionary action. Physicians of conscience and good will must unite to take back the future – or all freedoms, including freedom of choice in healthcare – will be lost forever.
APPENDIX A. LITERATURE REVIEW
This section presents a selection of published peer-reviewed studies that document the life-enhancing and/or life extending benefits of HRT in aging adults. For further references, see the A4M’s White Paper “Guidance for Physicians on Hormone Replacement Therapy”; A4M, May 2007; available at: http://www.worldhealth.net/white-papers-official-statements/
HGH
Aberg ND. Growth hormone increases connexin-43 expression in the cerebral cortex and hypothalamus. Endocrinology 2000 Oct; 141(10):3879-86
Abs R. Update on the diagnosis of GH deficiency in adults. Eur J Endocrinol. 2003 Apr; 148 Suppl 2:S3-8.
Adamopoulos S et al. Growth hormone administration reduces circulating proinflammatory cytokines and soluble Fas/soluble Fas ligand system in patients with chronic heart failure secondary to idiopathic dilated cardiomyopathy. Am Heart J 2002 Aug;144(2):359-64
Aimaretti G et al. Diagnostic reliability of a single IGF-I measurement in 237 adults with total anterior hypopituitarism and severe GH deficiency.Clin Endocrinol (Oxf). 2003 Jul; 59(1):56-61
Albert SG et al. Low-dose recombinant human growth hormone as adjuvant therapy to lifestyle modifications in the management of obesity.Clin Endocrinol Metab. 2004 Feb; 89(2):695-701.
Aleman et al. Insulin-Like Growth Factor-I and Cognitive Function in Healthy Older Men J Clin Endocrinol Metab 84:471–475, 1999
Andreassen et al. Concentrations of the acute phase reactants high-sensitive C-reactive protein and YKL-40 and of interleukin-6 before and after treatment in patients with acromegaly and growth hormone deficiency. Clin Endocrinol (Oxf). 2007 Aug 28
Baffa R et al. Low serum insulin-like growth factor 1 (IGF-1): a significant association with prostate cancer. Tech Urol 2000 Sep; 6(3):236-239
Bartke A et al. Consequences of growth hormone (GH) overexpression and GH resistance. Neuropeptides 2002 Apr;36(2-3):201
Baum HB et al. Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann Intern Med 1996 Dec 1; 125(11):883-90
Bengtsson BA, Edén S, Lönn L, et al. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab. 1993;76:309-317.
Bennett R Growth hormone in musculoskeletal pain states.Curr Rheumatol Rep. 2004 Aug; 6(4):266-73.
Bennett RM et al. A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia Am J Med. 1998 Mar; 104(3):227-31.
Besson A et al. Reduced longevity in untreated patients with isolated growth hormone deficiency. J Clin Endocrinol Metab. 2003 Aug; 88(8):3664-7.
Biller BM et al. Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab. 2002 May; 87(5):2067-79.
Blackman M et al. Growth Hormone and Sex Steroid Administration in Healthy Aged Women and Men. JAMA November 13, 2002. Vol 288 No 18.
Bocchi EA et al. Growth hormone for optimization of refractory heart failure treatment. Arq Bras Cardiol 1999 Oct; 73(4):391-8
Bogarin R et al. Growth hormone treatment and risk of recurrence or progression of brain tumors in children: a review. Childs Nerv Syst. 2009 Jan 14
Boguszewski CL, Meister LH, Zaninelli DC, Radominski RB. One year of GH replacement therapy with a fixed low-dose regimen improves body composition, bone mineral density and lipid profile of GH-deficient adults. Eur J Endocrinol. 2005;152:67-75.
Bohdanowicz-Pawlak A et al. Risk factors of cardiovascular disease in GH-deficient adults with hypopituitarism: a preliminary report. Med Sci Monit. 2006 Feb; 12(2):CR75-80.
Borson-Chazot F. et al. Decrease in Carotid Intima-Media Thickness after One Year Growth Hormone (GH) Treatment in Adults with GH Deficiency J Clin Endocrinol Metab 84: 1329–1333, 1999
Branski LK et al. Randomized Controlled Trial to Determine the Efficacy of Long-Term Growth Hormone Treatment in Severely Burned Children., Ann Surg. 2009 Sep 2
Burgess W et al. The immune-endocrine loop during aging: role of growth hormone and insulin-like growth factor-I. Neuroimmunomodulation 1999 Jan-Apr; 6(1-2):56-68
Caidahl K, Edén S, Bengtsson BA. Cardiovascular and renal effects of growth hormone. Clin Endocrinol (Oxf). 1994;40:393-400.
Cappola AR et al. Association of IGF-I levels with muscle strength and mobility in older women. J Clin Endocrinol Metab 2001 Sep; 86(9):4139-46
Cappola et al. Insulin-like growth factor I and interleukin-6 contribute synergistically to disability and mortality in older women JCEM, 2003 May; 88(5):2019-25.
Cenci MC, Soares DV, Spina LD, Brasil RR, Lobo PM, Michmacher E, Vaisman M, Boguszewski CL, Conceição FL. Comparison of two dose regimens of growth hormone (GH) with different target IGF-1 levels on glucose metabolism, lipid profile, cardiovascular function and anthropometric parameters in gh-deficient adults. Growth Horm IGF Res. 2012;22:116-121.
Chan et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science Vol 279 January 1998
Cherbonnier C et al. Potentiation of tumour apoptosis by human growth hormone via glutathione production and decreased NF-kappaB activity. Br J Cancer.